Physicochemical Properties
| Molecular Formula | C35H60O7 |
| Molecular Weight | 592.84700 |
| Exact Mass | 592.433 |
| CAS # | 112137-81-2 |
| PubChem CID | 13193018 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 704.8±60.0 °C at 760 mmHg |
| Flash Point | 380.0±32.9 °C |
| Vapour Pressure | 0.0±5.1 mmHg at 25°C |
| Index of Refraction | 1.563 |
| LogP | 6.87 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 9 |
| Heavy Atom Count | 42 |
| Complexity | 954 |
| Defined Atom Stereocenter Count | 15 |
| SMILES | CC[C@H](CC[C@@H](C)[C@@H]1[C@]2(CC[C@@H]3[C@]4(CC[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4=C[C@@H](O)[C@H]3[C@@H]2CC1)C)C)C(C)C |
| InChi Key | CPVAKQVYNLPUBL-MSLCHGNTSA-N |
| InChi Code | InChI=1S/C35H60O7/c1-7-21(19(2)3)9-8-20(4)24-10-11-25-29-26(13-15-35(24,25)6)34(5)14-12-23(16-22(34)17-27(29)37)41-33-32(40)31(39)30(38)28(18-36)42-33/h17,19-21,23-33,36-40H,7-16,18H2,1-6H3/t20-,21-,23+,24-,25+,26+,27-,28-,29+,30-,31+,32-,33-,34+,35-/m1/s1 |
| Chemical Name | (2R,3R,4S,5S,6R)-2-[[(3S,7S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-7-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol |
| Synonyms | Ikshusterol 3-O-glucoside; 112137-81-2; Ikshusterol 3-O-beta-D-glucopyraside; (2R,3R,4S,5S,6R)-2-[[(3S,7S,8S,9S,10R,13R,14S,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-7-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; DTXSID501204652; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | PLA2 |
| ln Vitro | Ethnomedicinal plant extracts and their isolates have demonstrated significant inhibitory effect against various snake venom PLA2s enzymes activities and therefore can be used as an alternative against snake envenomation. Different phytochemicals capable of inhibiting PLA2s from different snake venoms have been isolated, these include Ikshusterol-3-O-glucoside, Betulin and Betulinic acid, Ar tumerone, 12- methoxy-4-methylvoachalotine, aristolochic acid, luteolin, kaempferol, isoquercitin, rutin, ellagic acid, gallic acid quinic acid, ferulic acid, caffeic acid, propylgallate, epigallocatechin gallate, 4- nerolidylcatechol, sitosterol, stigmasterol, 7-methoxy-coumarin, 6,7- methylenedioxy-coumarin, umbelliferone and tannic acid. These phytochemicals might provide a cheaper and new strategy for the development of new pharmaceutical drugs and alternative approaches for the treatment of snake envenomation. This review, presents a compilation of important phytochemicals that are effective against snake venom PLA2s activity due to their neutralization effect [1]. |
| References |
[1]. Ethnomedicinal plants: A source of phytochemical compounds against snake venom PLA2s activity. Journal of Pharmacognosy and Phytochemistry, 2020, 9(2): 1270-1275. |
| Additional Infomation | Ethnomedicinal plant extracts and their isolated compounds have demonstrated significant inhibitory effect against various snake venom PLA2s enzymes activities, this reveals the potential use of these phytochemicals in the development of new anti-snake therapies. Thus, ethnomedicinal plants are the most significant source of bioactive compounds that leads for new anti-venom serum development.[1] |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6868 mL | 8.4338 mL | 16.8677 mL | |
| 5 mM | 0.3374 mL | 1.6868 mL | 3.3735 mL | |
| 10 mM | 0.1687 mL | 0.8434 mL | 1.6868 mL |